ORLANDO, FL – March, 20th 2020 – Anubis Bio, the parent company behind DoggyStat, the first product of its kind to use passive immunity to treat canine diarrhea, announced today the close of a $1 million dollar seed round of venture financing. Led by Life Science Angels, the premier angel investment group focused solely on healthcare investing, and with participation from Freada Kapor Klein, Founding Partner at Kapor Capital. The funding round represents a strong pledge of confidence for the innovative science that Anubis Bio is applying to the space of canine diarrhea, with DoggyStat.
Pet diarrhea costs an estimated $3 billion per year in medical services and products, accounting for as many as 40 million U.S. vet visits annually. Until the launch of DoggyStat, only strong antibiotics and less reliable probiotics have been available for the treatment of pet diarrhea.
For Anubis Bio, DoggyStat represents the first product based on patented technology that leverages passive immunity to treat infections in animals. Passive immunity is the process of using transferred antibodies, rather than those actively produced by the animal, to treat infection and disease, making it a safe and powerful healthcare technology. It is used in a variety of medical applications in humans and animals DoggyStat is formulated to resolve diarrhea from several canine bacterial and viral pathogens, enabling safe and rapid resolution of acute canine diarrhea. Anubis Bio plans to apply the science behind DoggyStat to a myriad of other animal infections, starting with common GI tract pathogens found in cats, horses, and swine.
DoggyStat is also being investigated for the treatment of canine parvovirus with exciting initial results. In a recent parvovirus field trial DoggyStat resolved diarrhea symptoms within 24 hours in nine out of ten parvo-positive dogs, all of whom then survived this potentially fatal canine infection. Given these promising results, Anubis Bio plans to conduct a broader trial and publish results later this year.
DoggyStat is a safe, easy to use, dietary supplement that rapidly resolves acute canine diarrhea. The mixture of bovine colostrum and hyperimmunized egg powder delivers fast-acting antibodies to the GI tract that work with a dog’s system to neutralize bacterial and viral pathogens to relieve diarrhea and restore normal gut function. A single dose typically resolves diarrhea within 12-24 hours. Administration of DoggyStat is simple, the powder can be mixed with food or water and fed to the pet; animals find it very palatable. DoggyStat has no known side effects or overdose risk making it safe for dogs of all ages and sizes.
DoggyStat is available wholesale via RJ Matthews, with over 20,000 pet retailer accounts nationwide; VetCove, the largest B2B veterinary marketplace, serving over 7,000 vet clinics and hospitals; and Anubis Bio wholesale direct (wholesale.doggystat.com). Retail DoggyStat is available through Amazon and doggystat.com.
ABOUT ANUBIS BIO
Anubis Bio is an animal health company employing passive immunity to develop products for the treatment of infections in animals. Founded in 2019, and led by experienced CEO Tom Schultz, who has founded multiple technology companies, including those with IPO, NASDAQ, and 9-figure exits. Tom holds a B.E.S degree from Johns Hopkins University and an MBA from Harvard Business School. The Company has assembled a strong group of directors and advisors to help build the business and recruit an effective management team. The company’s lead product, DoggyStat, delivers fast-acting immune factors to the GI tract to support rapid relief of acute canine diarrhea.
Tom Schultz, 480-231-7832